Inflammation Programs
Not Specified
Not SpecifiedPlans outlined for 2026
Key Facts
About Arcus Biosciences
Arcus Biosciences is a Hayward, California-based oncology company pioneering the development of combination cancer therapies. Founded in 2015 by industry veterans Terry Rosen and Juan Jaen, the company has built an integrated platform from discovery through commercialization, advancing molecules from IND to Phase 1 in as little as 18 months. With a focus on well-understood biological pathways, Arcus aims to accelerate the delivery of new treatment options through strategic partnerships with the cancer community and a pipeline featuring both oncology and inflammation programs.
View full company profileTherapeutic Areas
Other Not Specified Drugs
| Drug | Company | Phase |
|---|---|---|
| Bone Marrow Conditioning Program | Telix Pharmaceuticals | Pipeline |
| AGMB-447 | Agomab Therapeutics | Not Disclosed |
| AGMB-101 | Agomab Therapeutics | Not Disclosed |
| TRIFERTY-ATM® | Laboratorio Reig Jofre | Approved/Commercial |
| AGEN1571 (anti-ILT2) | Agenus | Not specified |
| AGEN1777 | Agenus | Not specified |
| AGEN1721 | Agenus | Not specified |
| INCAGN1876 (GITR Agonist) | Agenus | Not specified |
| INCAGN1949 (OX40 Agonist) | Agenus | Not specified |
| AGEN1327 (anti-TIGIT) | Agenus | Not specified |
| AGEN2373 (CD137 Agonist) | Agenus | Not specified |
| AGENT-797 (iNKT Cell Therapy) | Agenus | Not specified |